25 related articles for article (PubMed ID: 19953928)
1. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
2. Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.
Musch E; Malek M; Chrissafidou A
Ann Hematol; 2003 Apr; 82(4):244-6. PubMed ID: 12707729
[TBL] [Abstract][Full Text] [Related]
3. Amifostine in the treatment of low-risk myelodysplastic syndromes.
Grossi A; Fabbri A; Santini V; Leoni F; Nozzoli C; Longo G; Pagliai G; Ciolli S; Rossi Ferrini P
Haematologica; 2000 Apr; 85(4):367-71. PubMed ID: 10756361
[TBL] [Abstract][Full Text] [Related]
4. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
5. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
[TBL] [Abstract][Full Text] [Related]
6. [Application of bioinformatics analysis to optimize amifostine combination therapeutic regimen of myelodysplastic syndrome].
Lu XC; Yang B; Zhu HL; Fan H; Li SX; Liu Y; Yao SQ
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(26):1834-7. PubMed ID: 19953928
[TBL] [Abstract][Full Text] [Related]
7. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
Cazzola M
Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
[TBL] [Abstract][Full Text] [Related]
8. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
Beran M
Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
[TBL] [Abstract][Full Text] [Related]
9. [Mechanism and problem of amifostine in treating myelodysplastic syndromes].
Dang YH; Li W; Yang B; Zhu HL; Huang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1597-601. PubMed ID: 20030955
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?
List AF
Leuk Res; 1998 May; 22 Suppl 1():S7-11. PubMed ID: 9734693
[No Abstract] [Full Text] [Related]
11. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia.
List AF
Semin Oncol; 1999 Apr; 26(2 Suppl 7):61-5. PubMed ID: 10348262
[TBL] [Abstract][Full Text] [Related]
12. Developmental therapeutics for myelodysplastic syndromes.
Naing A; Sokol L; List AF
J Natl Compr Canc Netw; 2006 Jan; 4(1):78-82. PubMed ID: 16403406
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]